How Version Control Breaks Down Across 14 Authors and 6 Review Rounds
The Confluence review workflow that feels like version control isn't actually performing cross-section consistency checking. Each functional team reviews its own section for accuracy within its domain. The regulatory lead is supposed to catch inconsistencies at integration, but by the time six review rounds have run across clinical, statistical, CMC, and benefit-risk sections, the cognitive load of tracking every quantitative claim against every other section that references it is beyond what a single reviewer can reliably do under deadline pressure. An FDA AdCom internal inconsistency finding — a benefit-risk conclusion that doesn't align with the statistical endpoint characterization, or a safety claim in the briefing document that contradicts the clinical summary — can trigger questions from advisory committee members that the sponsor wasn't prepared to answer. For a large-cap pharma with an NDA pending AdCom, that kind of unforced error is unacceptable.
What an Agent Does Across Vault RIM, Medidata, and ArisGlobal LifeSphere
An AI Labor Company AdCom consistency review agent extracts cross-section checking logic from Vault RIM briefing document histories and your Confluence review pattern records. Once the briefing document is in active review, the agent runs daily cross-referencing across all sections — identifying cases where the same clinical endpoint is characterized differently in the clinical and statistical sections, where benefit-risk language doesn't align with the quantitative claims it summarizes, or where safety incidence figures in the briefing document diverge from the Medidata Rave source data. Inconsistencies are flagged to the regulatory VP before each review round closes, with specific section references and the nature of the discrepancy. A version-locked consistency report is maintained through final submission. The agent is typically operational within fourteen weeks of engagement start.
The Business Case: Protecting a Multi-Billion-Dollar Regulatory Outcome
FDA AdCom preparation costs $3M–$15M per submission cycle. That investment funds clinical data packages, statistical analysis, regulatory strategy, and the briefing document itself — and it all rides on what happens in the AdCom meeting. An inconsistency finding from the FDA or an advisory committee member in that room doesn't just create a difficult question to answer; it signals to the committee that the sponsor's data package wasn't internally rigorous. The reputational and regulatory consequences of a poorly-received AdCom presentation can extend well beyond the specific submission. An agent that catches inconsistencies during the review cycle — rather than after the document is submitted — protects the outcome of an investment that already dwarfs the cost of the automation. The 40–60% reduction in manual cross-checking time also returns regulatory team capacity during the most compressed period of the review cycle, when it's most needed.
Does the agent replace the regulatory lead's review, or supplement it?
It supplements. The agent handles systematic cross-referencing of quantitative claims across sections — the part of the review that's high-volume and easy to miss under deadline pressure. Regulatory judgment about how to resolve inconsistencies, how to frame benefit-risk conclusions, and what to prioritize in the AdCom presentation stays with your regulatory VP and team.
How does the agent handle sections that are still in draft when daily reviews run?
The agent runs cross-referencing against the current state of each section at the time of the daily review, and flags are tagged to specific version snapshots in Vault RIM. Draft sections are reviewed as they stand — inconsistencies flagged against a draft are tracked through to resolution and confirmed against the final version before submission.
Can the agent cross-reference claims in the briefing document against the underlying Medidata Rave trial data?
Yes. For quantitative claims — endpoint incidence rates, safety figures, p-values — the agent can cross-reference the briefing document language against the structured Medidata Rave outputs to flag cases where the stated figure diverges from the source data. The scope of source-data cross-referencing is defined during the fourteen-week onboarding.